{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:52:17Z","timestamp":1792212737313,"version":"4.4.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/jcp.0b013e318272d10c","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T10:17:20Z","timestamp":1352197040000},"page":"778-786","source":"Crossref","is-referenced-by-count":14,"title":["Cognitive Effects of a Single Dose of Atypical Antipsychotics in Healthy Volunteers Compared With Placebo or Haloperidol"],"prefix":"10.1097","volume":"32","author":[{"given":"Young-Chul","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Chul","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Biao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Young","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Gul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","first-page":"119","article-title":"Braff DL, et al..","volume":"26","author":"Green","year":"2000","journal-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff Schizophr Bull"},{"key":"R2-8-20210128","first-page":"321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia Am J Psychiatry.","volume":"153","author":"Green","year":"1996","journal-title":""},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","article-title":"A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.","volume":"55","author":"Mishara","year":"2004","journal-title":"Biol Psychiatry"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","article-title":". A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects.","volume":"89","author":"Woodward","year":"2007","journal-title":"Schizophr Res"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":". The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr Bull"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":". A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.","volume":"8","author":"Woodward","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":". Neurocognitive effects of antipsychotics medication in patients with chronic schizophrenia in the CATIE trial.","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":". Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).","volume":"166","author":"Davidson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/archpsyc.63.11.1189","article-title":". Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.","volume":"63","author":"Reilly","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.biopsych.2006.10.031","article-title":". Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia.","volume":"62","author":"Reilly","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2125.1999.00021.x","article-title":". Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers.","volume":"48","author":"Hughes","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-002-1272-2","article-title":". Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.","volume":"165","author":"Allain","year":"2003","journal-title":"Psychopharmacology"},{"key":"R13-8-20210128","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/0269881104042614","article-title":". Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers.","volume":"18","author":"Barrett","year":"2004","journal-title":"J Psychopharmacol"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/jcp.0b013e31802dfff0","article-title":". Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration.","volume":"27","author":"Morrens","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/0269881106071550","article-title":". The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.","volume":"21","author":"Wezenberg","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/026988110001400206","article-title":". The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers.","volume":"14","author":"Legangneux","year":"2000","journal-title":"J Psychopharmacol"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism.","volume":"60","author":"Grunder","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pnpbp.2010.10.021","article-title":"An unblended comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.","volume":"35","author":"Suzuki","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","article-title":". Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.","volume":"32","author":"Kim","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","article-title":"The use of analogue scales in rating subjective feelings.","volume":"47","author":"Bond","year":"1974","journal-title":"Br J Med Psychol"},{"key":"R25-8-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R26-8-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R27-8-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/00023210-199606030-00006","article-title":"Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia.","volume":"6","author":"Coukell","year":"1996","journal-title":"CNS Drugs"},{"key":"R28-8-20210128","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.","volume":"26","author":"DeLeon","year":"2004","journal-title":"Clin Ther"},{"key":"R29-8-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2165\/00003088-198917060-00004","article-title":". Pharmacokinetics of haloperidol.","volume":"17","author":"Froemming","year":"1989","journal-title":"Clin Pharmacokinetics"},{"key":"R30-8-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199503000-00003","article-title":"A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.","volume":"10","author":"He","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"R31-8-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s002130050396","article-title":". The effects of haloperidol on visual search, eye movements and psychomotor performance.","volume":"133","author":"Lynch","year":"1997","journal-title":"Psychopharmacology"},{"key":"R32-8-20210128","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/(SICI)1099-1077(1998100)13:7<493::AID-HUP25>3.0.CO;2-A","article-title":". Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers.","volume":"13","author":"Perault","year":"1998","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"R33-8-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2125.1992.tb04109.x","article-title":"Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG.","volume":"34","author":"Leigh","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"R34-8-20210128","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/sj.npp.1300803","article-title":". Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans.","volume":"30","author":"Lile","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R35-8-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/026988119901300207","article-title":". A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers.","volume":"13","author":"Beuzen","year":"1999","journal-title":"J Psychopharmacol"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1076\/clin.13.3.283.1743","article-title":"Practice effects on commonly used measures of executive function across twelve months.","volume":"13","author":"Basso","year":"1999","journal-title":"Clin Neuropsychol"},{"key":"R37-8-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0006-8993(97)00649-5","article-title":". Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.","volume":"768","author":"Cudennec","year":"1997","journal-title":"Brain Res"},{"key":"R38-8-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-3565(24)37762-6","article-title":". Effects of acute and repeated administration of amisulpride, a dopamine D2D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons.","volume":"287","author":"Giovanni","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"R39-8-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","article-title":". Psychopharmacological profile of amisulpride, an antipsychotic drug with selective presynaptic D2D3 dopamine receptor antagonist activity and limbic selectivity.","volume":"280","author":"Perrault","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R40-8-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/JCP.0b013e31819a6995","article-title":". Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls.","volume":"29","author":"Ahn","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R41-8-20210128","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats.","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology"},{"key":"R42-8-20210128","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":". Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R43-8-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":". Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R44-8-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0301-0082(02)00011-4","article-title":"Dopamine and the regulation of cognition and attention.","volume":"67","author":"Nieoullon","year":"2002","journal-title":"Prog Neurobiol"},{"key":"R45-8-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s002130100851","article-title":". Improved short-term spatial memory but impaired reversal learning following the dopamine D2 agonist bromocriptine in human behavior.","volume":"159","author":"Mehta","year":"2001","journal-title":"Psychopharmacology"},{"key":"R46-8-20210128","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1126\/science.287.5460.2020","article-title":"Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation.","volume":"17","author":"Castner","year":"2000","journal-title":"Science"},{"key":"R48-8-20210128","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","article-title":". The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine.","volume":"187","author":"Kern","year":"2006","journal-title":"Psychopharmacology"},{"key":"R49-8-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.schres.2010.01.022","article-title":". Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation.","volume":"118","author":"Schlagenhauf","year":"2010","journal-title":"Schizophr Res"},{"key":"R50-8-20210128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuropharm.2007.10.010","article-title":". Effects of aripiprazoleOPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.","volume":"54","author":"Nordquist","year":"2008","journal-title":"Neuropharmacology"},{"key":"R51-8-20210128","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.","volume":"64","author":"Harrison","year":"2004","journal-title":"Drugs"},{"key":"R52-8-20210128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0091270003261901","article-title":"Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.","volume":"44","author":"Mallikaarjun","year":"2004","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318272d10c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T09:16:32Z","timestamp":1745140592000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201212000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318272d10c","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}